Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors

摘要: The treatment for patients with unknown primary carcinoma, particularly those unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 newer drugs have improved overall survival compared retrospective historical data prospective clinical from 1967 2000. Long-term (1, 2, 3 years beyond) been documented a small minority of by several recent trials. number other advanced adenocarcinomas known sites (colon, rectum, lung, pancreas) use alone or combined targeted (bevacizumab, erlotinib), about 60% harbor occult lesions colon, pancreas. Many these benefited broad-spectrum regimens. Several regimens appear same currently represent choice majority patients. Improvements diagnostic pathology molecular characterization carcinomas are likely soon help select more appropriate tailored therapies many